177 related articles for article (PubMed ID: 32843973)
1. Diabetes mellitus type 2 drives metabolic reprogramming to promote pancreatic cancer growth.
Velazquez-Torres G; Fuentes-Mattei E; Choi HH; Yeung SJ; Meng X; Lee MH
Gastroenterol Rep (Oxf); 2020 Aug; 8(4):261-276. PubMed ID: 32843973
[TBL] [Abstract][Full Text] [Related]
2. Impact of diabetes on promoting the growth of breast cancer.
Chou PC; Choi HH; Huang Y; Fuentes-Mattei E; Velazquez-Torres G; Zhang F; Phan L; Lee J; Shi Y; Bankson JA; Wu Y; Wang H; Zhao R; Yeung SJ; Lee MH
Cancer Commun (Lond); 2021 May; 41(5):414-431. PubMed ID: 33609419
[TBL] [Abstract][Full Text] [Related]
3. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.
Fuentes-Mattei E; Velazquez-Torres G; Phan L; Zhang F; Chou PC; Shin JH; Choi HH; Chen JS; Zhao R; Chen J; Gully C; Carlock C; Qi Y; Zhang Y; Wu Y; Esteva FJ; Luo Y; McKeehan WL; Ensor J; Hortobagyi GN; Pusztai L; Fraser Symmans W; Lee MH; Yeung SC
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957076
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic Analyses and Potential Therapeutic Targets of Pancreatic Cancer With Concomitant Diabetes.
Xu T; Xu X; Liu PC; Mao H; Ju S
Front Oncol; 2020; 10():563527. PubMed ID: 33251135
[TBL] [Abstract][Full Text] [Related]
5. Metformin inhibits TGF‑β1‑induced epithelial‑mesenchymal transition and liver metastasis of pancreatic cancer cells.
Yoshida J; Ishikawa T; Endo Y; Matsumura S; Ota T; Mizushima K; Hirai Y; Oka K; Okayama T; Sakamoto N; Inoue K; Kamada K; Uchiyama K; Takagi T; Naito Y; Itoh Y
Oncol Rep; 2020 Jul; 44(1):371-381. PubMed ID: 32627027
[TBL] [Abstract][Full Text] [Related]
6. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells.
Karnevi E; Said K; Andersson R; Rosendahl AH
BMC Cancer; 2013 May; 13():235. PubMed ID: 23663483
[TBL] [Abstract][Full Text] [Related]
7. Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages.
Incio J; Suboj P; Chin SM; Vardam-Kaur T; Liu H; Hato T; Babykutty S; Chen I; Deshpande V; Jain RK; Fukumura D
PLoS One; 2015; 10(12):e0141392. PubMed ID: 26641266
[TBL] [Abstract][Full Text] [Related]
8. Impact of diabetes type II and chronic inflammation on pancreatic cancer.
Zechner D; Radecke T; Amme J; Bürtin F; Albert AC; Partecke LI; Vollmar B
BMC Cancer; 2015 Feb; 15():51. PubMed ID: 25885700
[TBL] [Abstract][Full Text] [Related]
9. Diabetes mellitus stimulates pancreatic cancer growth and epithelial-mesenchymal transition-mediated metastasis via a p38 MAPK pathway.
Wang L; Bai YY; Yang Y; Hu F; Wang Y; Yu Z; Cheng Z; Zhou J
Oncotarget; 2016 Jun; 7(25):38539-38550. PubMed ID: 27413117
[TBL] [Abstract][Full Text] [Related]
10. The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth.
Soliman GA; Shukla SK; Etekpo A; Gunda V; Steenson SM; Gautam N; Alnouti Y; Singh PK
Curr Dev Nutr; 2020 Sep; 4(9):nzaa131. PubMed ID: 32908958
[TBL] [Abstract][Full Text] [Related]
11. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
12. The Influence of Metformin on Serum Carbohydrate Antigen 19-9 (CA 19-9) Levels in Type 2 Diabetes Mellitus Patients.
Ankit BS; Agrawal R; Gadhwal A; Chahar C; Agrawal RP
J Assoc Physicians India; 2018 Mar; 66(3):38-41. PubMed ID: 30341867
[TBL] [Abstract][Full Text] [Related]
13. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth.
Kisfalvi K; Eibl G; Sinnett-Smith J; Rozengurt E
Cancer Res; 2009 Aug; 69(16):6539-45. PubMed ID: 19679549
[TBL] [Abstract][Full Text] [Related]
14. Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes.
Stafford JM; Elasy T
Vasc Health Risk Manag; 2007; 3(4):503-10. PubMed ID: 17969380
[TBL] [Abstract][Full Text] [Related]
15. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer.
Chen K; Qian W; Jiang Z; Cheng L; Li J; Sun L; Zhou C; Gao L; Lei M; Yan B; Cao J; Duan W; Ma Q
Mol Cancer; 2017 Jul; 16(1):131. PubMed ID: 28738823
[TBL] [Abstract][Full Text] [Related]
16. Effects of first-line diabetes therapy with biguanides, sulphonylurea and thiazolidinediones on the differentiation, proliferation and apoptosis of islet cell populations.
Sarnobat D; Moffett RC; Flatt PR; Tarasov AI
J Endocrinol Invest; 2022 Jan; 45(1):95-103. PubMed ID: 34191257
[TBL] [Abstract][Full Text] [Related]
17. Diabetes and pancreatic cancer.
Li D
Mol Carcinog; 2012 Jan; 51(1):64-74. PubMed ID: 22162232
[TBL] [Abstract][Full Text] [Related]
18. Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome.
Sinha SK; Bhangoo A; Anhalt H; Maclaren N; Marshall JD; Collin GB; Naggert JK; Ten S
J Pediatr Endocrinol Metab; 2007 Sep; 20(9):1045-52. PubMed ID: 18038714
[TBL] [Abstract][Full Text] [Related]
19. Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms.
Cifarelli V; Lashinger LM; Devlin KL; Dunlap SM; Huang J; Kaaks R; Pollak MN; Hursting SD
Diabetes; 2015 May; 64(5):1632-42. PubMed ID: 25576058
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.
Rozengurt E; Sinnett-Smith J; Kisfalvi K
Clin Cancer Res; 2010 May; 16(9):2505-11. PubMed ID: 20388847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
